Clinical research for non-linearity of efflux pathway and drug-drug interaction via efflux-type transporter at digestive tract - sulfasalazine clinical research

APDD0 个研究点目标入组 8 人开始时间: 2009年11月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•the investigors must ensure that all subjects being considerd meet the following exclusion criteria or conditions: 1)any impairment of blood, liver and kidney 2)asthma 3)Acute Intermittent Porphyria 4)Glucose-6-phosphate dehydrogenase deficiency 5)any medication and food ingestion containing curcumin within 7 days prior to test drug administration 6)fruit juice ingestion containing grapefruit, orange or apple within 7 days prior to test drug administration 7)dialy user of St. John's wort 8)recent (past 4 months) participation in other clinical trial for investigational new chemical entity 9)donation of 400mL or more of blood within 12 weeks prior to participation, donation of 200mL or more of blood within 4 weeks prior to participation, or donation of component blood within 2 weeks prior to participation 10)positive results on HBs-AG, HCV-AB, HIV-AB, TPHA 11)history of allergy to any drugs and foods 12)history of drug or alcohol abuse and incapable of abstinence from smoking and alcohol during protocol designated period 13)excess daily alcohol ingestion 14)inappropriate subject as determined by physical examination, vital signs, laboartory tests and ECG at screening 15)history of sulfasalazine administration (either clinical research or medication) 16)vulnerable for alcohol intake 17)inappropriate subjects as determined by phsicians

发起方